Rituximab for the treatment of diffuse large B-cell lymphomas

References

• Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia. Canberra: Australian Institute of Health and Welfare (2003).
   Google Scholar
• Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol.17, 3835–3849 (1999).
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med.329, 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer38, 1484–1493 (1976).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med.328, 1002–1006 (1993).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. Management of diffuse large B-cell lymphoma in young patients. Am. J. Cancer4, 349–354 (2005).
   Google Scholar
• Strehl J, Mey U, Glasmacher A et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis. Haematologica88, 1304–1315 (2003).
   PubMed Web of Science ®Google Scholar
• Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J.7, 711–717 (1988).
   PubMed Web of Science ®Google Scholar
• Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J. Biol. Chem.264, 11282–11287 (1989).
   PubMed Web of Science ®Google Scholar
• Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J. Immunol.135, 973–979 (1985).
   PubMed Web of Science ®Google Scholar
• Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood83, 1390–1397 (1994).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Vose JM, Do KA et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br. J. Haematol.123, 850–857 (2003).
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood69, 584–591 (1987).
   PubMed Web of Science ®Google Scholar
• Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br. J. Haematol.121, 458–461 (2003).
   PubMed Web of Science ®Google Scholar
• Anolik J, Looney RJ, Bottaro A, Sanz I, Young F. Down-regulation of CD20 on B cells upon CD40 activation. Eur. J. Immunol.33, 2398–2409 (2003).
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today15, 450–454 (1994).
   PubMedGoogle Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm.12, 177–186 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol.30, 3–8 (2003).
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83, 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Roos D, dem Borne AE, de Haas M. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood90, 1109–1114 (1997).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21, 3940–3947 (2003).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood84, 2457–2466 (1994).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J. Clin. Oncol.15, 3266–3274 (1997).
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol.9, 995–1001 (1998).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90, 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood101, 466–468 (2003).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood92, 1927–1932 (1998).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol.17, 268–276 (1999).
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk. Lymphoma46, 1569–1573 (2005).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346, 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.23, 4117–4126 (2005).
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B-cell lymphoma. Blood102, 103a (2003).
   Google Scholar
• Grillo-Lopez AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev. Anticancer Ther.2, 323–329 (2002).
   PubMedGoogle Scholar
• Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.7, 379–391 (2006).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood104, 634–641 (2004).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Klöss M, Schmits R et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood106, 9a (2005).
   Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol.23, 5027–5033 (2005).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr. Transplant8, 9–21 (2004).
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Stanojevic S, Feuchtinger T et al. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant.36, 91–97 (2005).
   PubMed Web of Science ®Google Scholar
• de Vries MJ, Veerman AJ, Zwaan CM. Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin’s lymphoma. Br. J. Haematol.125, 414–415 (2004).
   PubMed Web of Science ®Google Scholar
• Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J. Clin. Oncol.19, 3439 (2001).
   PubMed Web of Science ®Google Scholar
• Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur. J. Haematol.72, 292–295 (2004).
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev.31, 456–473 (2005).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16, 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol.26, 79–87 (1999).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol.19, 2153–2164 (2001).
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin. Oncol.29, 105–112 (2002).
   PubMed Web of Science ®Google Scholar
• Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J. Clin. Oncol.17, 1962–1963 (1999).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol.17, 791–795 (1999).
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood94, 2217–2224 (1999).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol.21, 1746–1751 (2003).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood101, 6–14 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol.19, 2165–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin. Oncol.30, 483–492 (2003).
   PubMed Web of Science ®Google Scholar
• Altman A. Acute tumor lysis syndrome. Semin. Oncol.28, 3–8 (2001).
   PubMed Web of Science ®Google Scholar
• Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am. J. Med.94, 133–139 (1993).
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol.23, 4070–4078 (2005).
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br. J. Haematol.121, 913–918 (2003).
   PubMed Web of Science ®Google Scholar
• Saville MW, Benyunes MC, Multani PS. No clinical evidence for CD4+ cell depletion caused by rituximab. Blood102, 408–409 (2003).
   PubMed Web of Science ®Google Scholar
• Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N. Engl. J. Med.348, 2691–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica89, 361–363 (2004).
   PubMed Web of Science ®Google Scholar
• Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant33, 921–923 (2004).
   PubMed Web of Science ®Google Scholar
• Rose AL, Forsythe AM, Maloney DG. Agranulocytosis unresponsive to growth factors following rituximab in vivo purging. Blood101, 4225–4226 (2003).
   PubMed Web of Science ®Google Scholar
• Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N. Engl. J. Med.348, 2690–2691 (2003).
   PubMed Web of Science ®Google Scholar
• Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk. Lymphoma42, 1329–1337 (2001).
   PubMed Web of Science ®Google Scholar
• Swords R, Power D, Fay M, O’Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am. J. Hematol.77, 103–104 (2004).
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Rusconi C, Montalbetti L et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a Phase II study of feasibility and toxicity. Haematologica91, 496–502 (2006).
   PubMed Web of Science ®Google Scholar
• Hernandez JA, Diloy R, Salat D, del Rio N, Martinez X, Castellvi JM. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica88, ECR22 (2003).
   PubMedGoogle Scholar
• Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood102, 1930 (2003).
   PubMed Web of Science ®Google Scholar
• Hamaki T, Kami M, Kusumi E et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am. J. Hematol.68, 292–294 (2001).
   PubMed Web of Science ®Google Scholar
• Kami M, Hamaki T, Murashige N et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol. J.4, 159–162 (2003).
   PubMedGoogle Scholar
• Klepfish A, Schattner A, Shvidel L et al. Successful treatment of aggressive HIV-associated non-Hodgkin’s lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leuk. Lymphoma44, 349–351 (2003).
   PubMed Web of Science ®Google Scholar
• Maeda T, Yamada Y, Tawara M et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int. J. Hematol.74, 70–75 (2001).
   PubMed Web of Science ®Google Scholar
• Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann. Oncol.14, 1792 (2003).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol.18, 3135–3143 (2000).
   Google Scholar
• Lemieux B, Bouafia F, Thieblemont C et al. Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematol. J.5, 467–471 (2004).
   PubMedGoogle Scholar
• Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol.10, 655–661 (1999).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol.22, 4711–4716 (2004).
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood103, 777–783 (2004).
   PubMed Web of Science ®Google Scholar
• Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol. Assess.8(37), 1–82 (2004).
   Web of Science ®Google Scholar
• Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur. J. Haematol.74, 194–202 (2005).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med.352, 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J. Clin. Oncol.21, 1263–1270 (2003).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Huglo D, Martinelli G et al. Yttrium-90 ibritumomomab tiuxetan (Zevalin) induces high response rates in previosuly treated patients with diffuse large B cell lymphoma (DLBCL). Ann. Oncol.16(Suppl. 5), V54 (2005).
   Google Scholar
• Leonard JP, Coleman M, Ketas J et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol.23, 5044–5051 (2005).
   PubMed Web of Science ®Google Scholar
• Leonard J, Friedberg J, Younes A. Results from a Phase I/II study of galiximab (anti-CD80) in combination with rituximab (anti-CD20) for relapsed or refractory follicular NHL. Ann. Oncol.16(Suppl.), V71 (2005).
   Google Scholar
• Pfreundschuh M, Ho A, Wolf M et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: rituximab as and “equalizer” in the MInT study. J. Clin. Oncol.23, 566S (2005).
   Google Scholar